Journal: Proceedings of the National Academy of Sciences of the United States of America
Article Title: Fructose-2,6-bisphosphate restores DNA repair activity of PNKP and ameliorates neurodegenerative symptoms in Huntington's disease.
doi: 10.1073/pnas.2406308121
Figure Lengend Snippet: Fig. 4. F2,6BP mediated in cell rescue of the PNKP activity and TC-NHEJ repair in HD mice striatum-derived neuronal cells (Q-111). (A) Upper panel: Representative gel image of 3′-phosphatase activity of PNKP in the nuclear extract of Q-7 (lanes 2 and 3) and Q-111 (lanes 4 to 9) mice striatum-derived neuronal cells with mock treatment (Mock 1; lanes 2 and 4), treatment with K16ApoE carrier peptide alone (25 µM; Mock 2; lanes 3 and 5) or supplemented with F2,6BP (200 µM; 48 and 72 h) (lanes 6 and 7), or F1,6BP (lanes 8 and 9, 200 µM) in presence of carrier peptide. Lane 1: substrate only. Lane 10: purified PNKP (2 ng). Lower panel: Quantitation of the % released phosphate in the indicated lanes. Error bars show ±SD of the mean; n = 3, **P < 0.01; ***P < 0.005 between groups as indicated or compared to lanes 2 and 3. (B) Upper panel: The western blot shows the levels of PFKFB3 in the cytosolic (CE) and nuclear extracts (NE) of Q-7 and Q-111 cells. GAPDH: cytosolic loading control; HDAC2: used as nuclear loading control. Lower panel: Quantitation of the relative PFKFB3 levels after normalization with respective loading controls; n = 3, ***P < 0.005. (C) Upper panel: Amplification of each long amplicon (6 to 8 kb) and a small amplicon (~200 to 300 bp) of the transcribed (Tubb, Enolase, Neurod) genes to assess DNA strand break accumulation. Lower panel: The bar diagram represents the normalized (with short amplicon) relative band intensity with the mock-treated Q-7 sample arbitrarily set as 100. (D) Upper panel: Amplification of each long amplicon (6 to 8 kb) and a small amplicon (~200 to 300 bp) of the nontranscribed (Myh4, Myh6, and Myod) genes to assess DNA strand break accumulation. Lower panel: The bar diagram represents the normalized (with short amplicon) relative band intensity with the mock-treated Q-7 sample arbitrarily set as 100. For both C and D, Error bars show ±SD of the mean; n = 3, ***P < 0.005; ns P > 0.05 compared to lanes 1 and 2. (E) Crystal violet (CV)-stained Q-7 (Upper panel) and Q-111 (Lower panel) cells following mock treatment with carrier peptide (Left panels) and supplemented with F2,6BP (200 µM) in the presence of carrier peptide (Right panels) at 48 h post F2,6BP delivery. (F) Similar Crystal violet staining of Q-7 and Q-111 cells at 72 h post F2,6BP delivery. (G) The bar diagram shows the quantification of cell viability represented as CV-stained cell number/sq. mm area selected from five representative microscopic images of different fields captured independently. Error bars show ±SD of the mean; n = 3, ***P < 0.005 between indicated groups. (H) Left panel: The western blots show the levels of various proteins (indicated on the Right) in the nuclear extracts of Q-7 and Q-111 cells under indicated treatment conditions. HDAC2: used as nuclear loading control. Right panel: Quantitation of the relative p53BP1 and γH2AX levels after normalization with nuclear loading control HDAC2; n = 3, ***P < 0.005 between indicated groups.
Article Snippet: The membranes were blocked with 5% w/v skimmed milk in TBST buffer (1X TrisBuffered Saline, 0.1% Tween 20), then immunoblotted with appropriate antibodies [PNKP, PFKFB3, γ- H2AX (S139 residue; #9718S, Cell Signaling Technology), p53BP1 (S1778, #2675S Cell Signaling Technology), 53BP1, HDAC2, H2AX (total) (#2595S; Cell Signaling technology)].
Techniques: Activity Assay, Derivative Assay, Purification, Quantitation Assay, Western Blot, Control, Amplification, Staining